CDMO CordenPharma has acquired the finished drug product manufacturing business of Vifor Pharma Group, which is refocusing its manufacturing on nephrology and iron deficiency. This comprises sites at Fribourg and Ettingen in Switzerland, and Lisbon, Portugal. Terms were not disclosed. The deal is expected to close in Q1 2022.
Lonza has recently announced three specific investments in the pharma sector in recent weeks. It will build two new customer-dedicated conjugation suites for antibody-drug conjugates (ADCs) at Visp, Switzerland, while adding particle engineering and drug product development at two sites in the US.